USANA Health Sciences (NYSE:USNA) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

USANA Health Sciences, Inc. (NYSE:USNA)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $19.50 and traded as high as $22.32. USANA Health Sciences shares last traded at $22.0650, with a volume of 69,850 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Finally, Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

USANA Health Sciences Stock Up 0.2%

The company has a market capitalization of $407.32 million, a PE ratio of 46.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.73. The firm’s 50 day simple moving average is $19.34 and its 200 day simple moving average is $19.50.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17. The business had revenue of $250.22 million for the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. As a group, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Insider Activity

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the transaction, the director directly owned 4,230 shares in the company, valued at approximately $75,843.90. This represents a 36.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 17,660 shares of company stock valued at $336,579. Company insiders own 0.82% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of the business. Versant Capital Management Inc grew its position in USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after acquiring an additional 1,487 shares during the last quarter. National Bank of Canada FI increased its stake in USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the period. State of Wyoming bought a new stake in shares of USANA Health Sciences during the first quarter worth $57,000. Tower Research Capital LLC TRC lifted its position in shares of USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.